Advertisement
RMD vs SRDX
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is RMD is a StrongBuy and SRDX is a StrongBuy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
RMD’s FA Score shows that 0 FA rating(s) are green whileSRDX’s FA Score has 0 green FA rating(s).
- RMD’s FA Score: 0 green, 5 red.
- SRDX’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
RMD’s TA Score shows that 5 TA indicator(s) are bullish while SRDX’s TA Score has 5 bullish TA indicator(s).
- RMD’s TA Score: 5 bullish, 3 bearish.
- SRDX’s TA Score: 5 bullish, 4 bearish.
Price Growth
RMD (@Pharmaceuticals: Other) experienced а +2.03% price change this week, while SRDX (@Medical/Nursing Services) price change was 0.00% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +2.63%. For the same industry, the average monthly price growth was +3.38%, and the average quarterly price growth was +5.77%.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was +6.78%. For the same industry, the average monthly price growth was +0.32%, and the average quarterly price growth was +13.36%.
Reported Earning Dates
RMD is expected to report earnings on Jan 22, 2026.
SRDX is expected to report earnings on Feb 10, 2026.
Industries' Descriptions
@Pharmaceuticals: Other (+2.63% weekly)Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
@Medical/Nursing Services (+6.78% weekly)The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
| RMD | SRDX | RMD / SRDX | |
| Capitalization | 37.3B | 615M | 6,065% |
| EBITDA | 2B | -2.74M | -72,986% |
| Gain YTD | 12.864 | 8.535 | 151% |
| P/E Ratio | 26.19 | 43.23 | 61% |
| Revenue | 5.26B | 121M | 4,345% |
| Total Cash | N/A | 32.7M | - |
| Total Debt | 846M | 32.6M | 2,595% |
RMD | SRDX | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 17 | 50 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 37 Fair valued | 92 Overvalued | |
PROFIT vs RISK RATING 1..100 | 69 | 86 | |
SMR RATING 1..100 | 37 | 90 | |
PRICE GROWTH RATING 1..100 | 56 | 37 | |
P/E GROWTH RATING 1..100 | 68 | 92 | |
SEASONALITY SCORE 1..100 | n/a | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
RMD's Valuation (37) in the Medical Specialties industry is somewhat better than the same rating for SRDX (92). This means that RMD’s stock grew somewhat faster than SRDX’s over the last 12 months.
RMD's Profit vs Risk Rating (69) in the Medical Specialties industry is in the same range as SRDX (86). This means that RMD’s stock grew similarly to SRDX’s over the last 12 months.
RMD's SMR Rating (37) in the Medical Specialties industry is somewhat better than the same rating for SRDX (90). This means that RMD’s stock grew somewhat faster than SRDX’s over the last 12 months.
SRDX's Price Growth Rating (37) in the Medical Specialties industry is in the same range as RMD (56). This means that SRDX’s stock grew similarly to RMD’s over the last 12 months.
RMD's P/E Growth Rating (68) in the Medical Specialties industry is in the same range as SRDX (92). This means that RMD’s stock grew similarly to SRDX’s over the last 12 months.
| RMD | SRDX | |
|---|---|---|
| RSI ODDS (%) | 3 days ago 74% | 3 days ago 66% |
| Stochastic ODDS (%) | 3 days ago 58% | 3 days ago 75% |
| Momentum ODDS (%) | 3 days ago 67% | 3 days ago 64% |
| MACD ODDS (%) | 3 days ago 68% | N/A |
| TrendWeek ODDS (%) | 3 days ago 62% | 3 days ago 66% |
| TrendMonth ODDS (%) | 3 days ago 54% | 3 days ago 67% |
| Advances ODDS (%) | 13 days ago 61% | 13 days ago 65% |
| Declines ODDS (%) | 11 days ago 59% | N/A |
| BollingerBands ODDS (%) | 3 days ago 67% | 3 days ago 57% |
| Aroon ODDS (%) | 3 days ago 56% | 3 days ago 65% |
Advertisement
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| ZIPP | 29.05 | 0.78 | +2.77% |
| STKd 150% UBER & 150% TSLA ETF | |||
| ERH | 12.54 | 0.18 | +1.43% |
| Allspring Utilities and High Income Fund | |||
| SIXH | 38.94 | 0.14 | +0.37% |
| ETC 6 Meridian Hdg Eq-Idx Opt Strat ETF | |||
| IHI | 64.36 | 0.03 | +0.05% |
| iShares US Medical Devices ETF | |||
| SQEW | 35.24 | N/A | N/A |
| LeaderShares Equity Skew ETF | |||
SRDX and
Correlation & Price change
A.I.dvisor tells us that SRDX and BDX have been poorly correlated (+32% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that SRDX and BDX's prices will move in lockstep.
| Ticker / NAME | Correlation To SRDX | 1D Price Change % | ||
|---|---|---|---|---|
| SRDX | 100% | N/A | ||
| BDX - SRDX | 32% Poorly correlated | +0.06% | ||
| SIBN - SRDX | 31% Poorly correlated | -0.10% | ||
| ALGN - SRDX | 31% Poorly correlated | -0.03% | ||
| BLCO - SRDX | 29% Poorly correlated | -0.06% | ||
| ATRC - SRDX | 28% Poorly correlated | +0.25% | ||
More | ||||